Urolithin A

01 What is Urolithin A?

Urolithin A is not something you eat directly — it is a metabolite produced by specific gut bacteria when they break down ellagitannins found in pomegranates, walnuts, and berries. The problem? Only about 40% of people have the right gut bacteria to produce meaningful amounts. The other 60% get little to no urolithin A from dietary sources, regardless of how many pomegranates they eat. This is why supplemental urolithin A (commercialised as Mitopure by Timeline/Amazentis) has generated so much excitement. It bypasses the gut bacteria requirement entirely, delivering the active compound directly. And what it does is genuinely impressive: it triggers mitophagy — the selective recycling of damaged mitochondria. As mitochondria age and accumulate damage, they become less efficient at producing energy and start generating more reactive oxygen species. Mitophagy clears these dysfunctional mitochondria so healthy ones can replace them. It is like trading in your old car for a new one rather than paying increasingly expensive repair bills.

02 How Does It Work?

Urolithin A activates mitophagy through the PINK1/Parkin pathway — the same pathway that is defective in some forms of Parkinson's disease. When a mitochondrion becomes dysfunctional, PINK1 accumulates on its surface, recruiting Parkin, which tags it for autophagic destruction. Urolithin A enhances this surveillance system. The result: accelerated clearance of damaged mitochondria, improved mitochondrial membrane potential in remaining mitochondria, increased cellular ATP production, and reduced oxidative stress from leaky electron transport chains.

03 What Does The Research Say?

Strong clinical evidence for a relatively new supplement. A 2019 Nature Metabolism paper showed urolithin A improved mitochondrial and cellular health biomarkers in elderly humans. A 2022 JAMA Network Open trial showed improved muscle endurance (12% increase in distance walked) in older adults after 4 months. Amazentis/Timeline has published multiple human trials showing: improved mitochondrial biomarkers (citrate synthase, complex I/III), reduced inflammatory markers (CRP), and improved physical performance. The company holds the main patent (Mitopure), but the science is published in peer-reviewed journals. Animal studies show prevention of age-related muscle decline and neuroprotection.

04 Reported Dosages

Clinical trial dose: 500-1000mg daily. Mitopure (commercial product): 500mg urolithin A daily. Taken with food, typically in the morning. Effects on mitochondrial biomarkers seen within 4 weeks. No cycling appears necessary. Legal supplement.

05 Side Effects & Risks

Very well-tolerated in clinical trials. Mild GI effects in some participants. No significant adverse events reported. Safety established in multiple human trials up to 4 months duration. Longer-term safety data still accumulating.

06 Legal Status

Where to Buy

Affiliate links — we may earn a small commission at no extra cost to you.